Posters - NCDEU: An Annual Meeting Sponsored by ASCP

Featured Speakers
Regulatory Wrap-Up
Friday, June 1st from 10:15 am – 11:45 am
Regulatory Wrap-Up
Thomas Laughren, M.D., Food and Drug Administration
See previous bio
Karl Broich, M.D., Federal Institute for Drugs and Medical Devices
(BfArM, Germany)
See previous bio
Mitchell Mathis, M.D.
Food and Drug Administration
Dr. Mitchell Mathis is the Deputy Director of Division of
Psychiatry Products, Center for Drug Evaluation and Research at
the FDA. He is a graduate of the Uniformed Services University
of the Health Sciences School of Medicine in Bethesda,
Maryland. He trained in family practice at Malcolm Grow
USAF Medical Center in Maryland and in psychiatry at Walter
Reed Army Medical Center in Washington, D.C. He has been
practicing outpatient and emergency room psychiatry in D.C.
and Maryland since 2001. He is board certified by the American Board of Psychiatry
and Neurology.
Manuel Haas, PharmD, MSc
European Medical Agency
Manuel Haas is Head of the Central Nervous System and
Ophthalmology section in the European Medicines Agency’s
Safety and Efficacy Sector (Human Medicines Development
and Evaluation Unit). The “CNS” Section is responsible for
the management of pre- and post-authorisation activities
of centralised applications/marketing authorisations, and
particularly the Safety and Efficacy part, related to medicinal
products in the neurology, psychiatry and ophthalmology
therapeutic areas. He is a pharmacist by training, and holds a post-graduate diploma
in hospital pharmacy as well as a Masters in Drug Development and Registration.
He worked for several years in hospitals in France and the UK before joining the
pharmaceutical industry in regulatory affairs in 2003. Following this role he started with
the European Medicines Agency in 2004 as Scientific Administrator. He has been in his
current role since September 2009.
10